Role of microRNA-27a in down-regulation of angiogenic factor AGGF1 under hypoxia associated with high-grade bladder urothelial carcinoma

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 5, 2014, Pages 712-725

  Xu, Yan ^a   Zhou, Ming ^b   Wang, Jingjing ^a   Zhao, Yuanyuan ^a   Li, Sisi ^a   Zhou, Bisheng ^a   Su, Zhenhong ^a   Xu, Chengqi ^a   Xia, Yue ^c   Qian, Huijun ^c   Tu, Xin ^a   Xiao, Wei ^d   Chen, Xiaoping ^d   Chen, Qiuyun ^b   Wang, Qing K ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

AGGF1; Bladder urothelial carcinoma; Hypoxia; MiR 27a

Indexed keywords

AGGF1; BLADDER UROTHELIAL CARCINOMA; HYPOXIA; MIR-27A;

ANGIOGENIC PROTEINS; APOPTOSIS; BASE SEQUENCE; CELL HYPOXIA; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; HUMANS; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS;

EID: 84894528778     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.01.007     Document Type: Article

References (49)

1. Taylor C.T., Cummins E.P. The role of nf-κb in hypoxia-induced gene expression. Ann. N. Y. Acad. Sci. 2009, 1177:178-184.
2. Hammond E.M., Freiberg R.A., Giaccia A.J. The roles of chk 1 and chk 2 in hypoxia and reoxygenation. Cancer Lett. 2006, 238:161-167.
3. Okuyama H., Endo H., Akashika T., Kato K., Inoue M. Downregulation of c-myc protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res. 2010, 70:10213-10223.
4. Liu L., Simon M.C. Regulation of transcription and translation by hypoxia. Cancer Biol. Ther. 2004, 3:489-494.
5. Camps C., Buffa F.M., Colella S., Moore J., Sotiriou C., Sheldon H., Harris A.L., Gleadle J.M., Ragoussis J. Hsa-mir-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin. Cancer Res. 2008, 14:1340-1348.
6. Chan S.Y., Zhang Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. Microrna-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins iscu1/2. Cell Metab. 2009, 10:273-284.
7. Sarkar J., Gou D., Turaka P., Viktorova E., Ramchandran R., Raj J.U. Microrna-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L861-L871.
8. Bartel D.P., Chen C. Micromanagers of gene expression: the potentially widespread influence of metazoan micrornas. Nat. Rev. Genet. 2004, 5:396-400.
9. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some micrornas downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
10. Zhou B., Ma R., Si W., Li S., Xu Y., Tu X., Wang Q. Microrna-503 targets fgf2 and vegfa and inhibits tumor angiogenesis and growth. Cancer Lett. 2013, 333:159-169.
11. Wei Y., Schober A., Weber C. Pathogenic arterial remodeling: the good and bad of micrornas. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H1050-H1059.
12. Bueno M.J., Malumbres M. Micrornas and the cell cycle. Biochim. Biophys. Acta 2011, 1812:592-601.
13. Tian X., Kadaba R., You S., Liu M., Timur A.A., Yang L., Chen Q., Szafranski P., Rao S., Wu L., Housman D.E., DiCorleto P.E., Driscoll D.J., Borrow J., Wang Q. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004, 427:640-645.
14. Hu Y., Li L., Seidelmann S.B., Timur A.A., Shen P.H., Driscoll D.J., Wang Q.K. Identification of association of common aggf1 variants with susceptibility for Klippel-Trenaunay syndrome using the structure association program. Ann. Hum. Genet. 2008, 72:636-643.
15. Chen D., Li L., Tu X., Yin Z., Wang Q. Functional characterization of Klippel-Trenaunay syndrome gene aggf1 identifies a novel angiogenic signaling pathway for specification of vein differentiation and angiogenesis during embryogenesis. Hum. Mol. Genet. 2013, 22:963-976.
16. Li L., Chen D., Li J., Wang X., Wang N., Xu C., Wang Q.K. Aggf1 acts at the top of the genetic regulatory hierarchy in specification of hemangioblasts in zebrafish. Blood 2014, 123:501-508.
17. Lu Q., Yao Y., Yao Y., Liu S., Huang Y., Lu S., Bai Y., Zhou B., Xu Y., Li L., Wang N., Wang L., Zhang J., Cheng X., Qin G., Ma W., Xu C., Tu X., Wang Q. Angiogenic factor aggf1 promotes therapeutic angiogenesis in a mouse limb ischemia model. PLoS ONE 2012, 7:e46998.
18. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L., Kiemeney L., Kriegmair M., Montironi R., Murphy W.M., Sesterhenn I.A., Tachibana M., Weider J. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
19. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
20. Ayala De La Peña F., Kanasaki K., Kanasaki M., Tangirala N., Maeda G., Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J. Biol. Chem. 2011, 286:20778-20787.
21. Kausch I., Böhle A. Molecular aspects of bladder cancer: iii. Prognostic markers of bladder cancer. Eur. Urol. 2002, 41:15-29.
22. Ehdaie B., Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert. Rev. Anticancer. Ther. 2008, 8:1103-1110.
23. Mori A., Moser C., Lang S.A., Hackl C., Gottfried E., Kreutz M., Schlitt H.J., Geissler E.K., Stoeltzing O. Up-regulation of Krüppel-like factor 5 in pancreatic cancer is promoted by interleukin-1β signaling and hypoxia-inducible factor-1α. Mol. Cancer Res. 2009, 7:1390-1398.
24. Pennacchietti S., Michieli P., Galluzzo M., Mazzone M., Giordano S., Comoglio P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
25. Lee S., Chen T.T., Barber C.L., Jordan M.C., Murdock J., Desai S., Ferrara N., Nagy A., Roos K.P., Iruela-Arispe M.L. Autocrine vegf signaling is required for vascular homeostasis. Cell 2007, 130:691-703.
26. Grimson A., Farh K.K.H., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
27. Rehmsmeier M., Steffen P., Höchsmann M., Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517.
28. Betel D., Wilson M., Gabow A., Marks D.S., Sander C. The microRNA. Org resource: targets and expression. Nucleic Acids Res. 2008, 36:D149-D153.
29. Shounan Y., Feng X., O'Connell P.J. Apoptosis detection by annexin v binding: a novel method for the quantitation of cell-mediated cytotoxicity. J. Immunol. Methods 1998, 217:61-70.
30. Sund M., Zeisberg M., Kalluri R. Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology 2005, 129:2076-2091.
31. Zlobec I., Steele R., Compton C.C. Vegf as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer 2005, 104:2517-2521.
32. Mylona E., Alexandrou P., Giannopoulou I., Liapis G., Sofia M., Keramopoulos A., Nakopoulou L. The prognostic value of vascular endothelial growth factors (vegfs)-a and -b and their receptor, vegfr-1, in invasive breast carcinoma. Gynecol. Oncol. 2007, 104:557-563.
33. Theodoropoulos V.E., Lazaris A.C., Kastriotis I., Spiliadi C., Theodoropoulos G.E., Tsoukala V., Patsouris E., Sofras F. Evaluation of hypoxia-inducible factor 1α overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 2005, 95:425-431.
34. Jaakkola P., Mole D.R., Tian Y., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A.V., Hebestreit H.F., Mukherji M., Schofield C.J. Targeting of hif-alpha to the von Hippel-Lindau ubiquitylation complex by o2-regulated prolyl hydroxylation. Sci. Signal. 2001, 292:468.
35. Kuhn D.E., Martin M.M., Feldman D.S., Terry A.V., Nuovo G.J., Elton T.S. Experimental validation of miRNA targets. Methods 2008, 44:47-54.
36. Kulshreshtha R., Ferracin M., Wojcik S.E., Garzon R., Alder H., Agosto-Perez F.J., Davuluri R., Liu C., Croce C.M., Negrini M., Calin G.A., Ivan M. A microRNA signature of hypoxia. Mol. Cell. Biol. 2007, 27:1859-1867.
37. Folkman J., Shing Y. Angiogenesis. J. Biol. Chem. 1992, 267:10931-10934.
38. Pignot G., Bieche I., Vacher S., Güet C., Vieillefond A., Debré B., Lidereau R., Amsellem-Ouazana D. Large-scale real-time reverse transcription-pcr approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of vegfa as a major independent prognostic marker. Eur. Urol. 2009, 56:678-689.
39. Theodoropoulos V.E., Lazaris A.C., Sofras F., Gerzelis I., Tsoukala V., Ghikonti I., Manikas K., Kastriotis I. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 2004, 46:200-208.
40. Yang W., Sun T., Cao J., Liu F., Tian Y., Zhu W. Downregulation of mir-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp. Cell Res. 2012, 318:944-954.
41. Huang X., Ding L., Bennewith K.L., Tong R.T., Welford S.M., Ang K.K., Story M., Le Q., Giaccia A.J. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol. Cell 2009, 35:856-867.
42. Giannakakis A., Sandaltzopoulos R., Greshock J., Liang S., Huang J., Hasegawa K., Li C., O'Brien-Jenkins A., Katsaros D., Weber B.L. Mir-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7:255-264.
43. Zhang Z., Sun H., Dai H., Walsh R., Imakura M., Schelter J., Burchard J., Dai X., Chang A.N., Diaz R.L., Marszalek J.R., Bartz S.R., Carleton M., Cleary M.A., Linsley P.S., Grandori C. MicroRNA mir-210 modulates cellular response to hypoxia through the myc antagonist mnt. Cell Cycle 2009, 8:2756-2768.
44. Fasanaro P., D'Alessandra Y., Di Stefano V., Melchionna R., Romani S., Pompilio G., Capogrossi M.C., Martelli F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-a3. J. Biol. Chem. 2008, 283:15878-15883.
45. Lee D., Romero R., Kim J., Tarca A.L., Montenegro D., Pineles B.L., Kim E., Lee J., Kim S.Y., Draghici S., Mittal P., Kusanovic J.P., Chaiworapongsa T., Hassan S.S., Kim C.J. Mir-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am. J. Pathol. 2011, 179:590-602.
46. Polytarchou C., Iliopoulos D., Hatziapostolou M., Kottakis F., Maroulakou I., Struhl K., Tsichlis P.N. Akt2 regulates all akt isoforms and promotes resistance to hypoxia through induction of mir-21 upon oxygen deprivation. Cancer Res. 2011, 71:4720-4731.
47. Yan H., Xue G., Mei Q., Wang Y., Ding F., Liu M., Lu M., Tang Y., Yu H., Sun S. Repression of the mir-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J. 2009, 28:2719-2732.
48. Mahajan A., Yuan C., Lee H., Chen E.S.W., Wu P., Tsai M. Structure and function of the phosphothreonine-specific fha domain. Sci. Signal. 2008, 1:e12.
49. Aravind L., Koonin E.V. G-patch: a new conserved domain in eukaryotic RNA-processing proteins and type d retroviral polyproteins. Trends Biochem. Sci. 1999, 24:342-344.